RE:RE:RE:RE:Medicago bought out for $357mwell, there is and there isnt. I'd start with the marketcap. KNE's is around $7 mil and MDGs is $357m. the potential for upside is equally lobsided, albeit tilted in KNEs favor.
i followed medicago since their marketcap was at $4m. i watched them go through just as much frustration as weve seen with KNE, or any other biotech for that mattter. MDG did not have 5 analysts covering the story until they had many significant milestones. certainly none in their preclinical stage where they had spectacular results and were telegraphing to us, early investors, that soon enough we would witness a successful development.
KNE is at the same point. they have an ongoing deal with the Army, their animal product is good, and they are slowly pursuing their pre clinical program. one thimg we have to understand about biotechs is that deals happen very slowly. MDG is a prime example. PMI was an early investor with MDG, owning I believe somethimg like 45% of the co since 2009 only to buy them now in 2013 (they are a partner in the takeover).
I think KNE has a great potential to land deals on at least 2 fronts. I've had very low expectation on when that may be, but I do know that my investment at $0.08 will at least double, if not quadruple, eventually.
TB
follow me on twitter: [url=https://twitter.com/technicalbuy]tb on twitter[/url]